Center for Substance Abuse Prevention; Notice of Meeting, 36557-36558 [2011-15374]

Download as PDF mstockstill on DSK4VPTVN1PROD with NOTICES Federal Register / Vol. 76, No. 120 / Wednesday, June 22, 2011 / Notices Government of the United States of America. The prospective exclusive license territory may be worldwide, and the field of use may be limited to: The use of ulipristal acetate for the treatment of symptomatic uterine fibroids. DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 22, 2011 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Patrick P. McCue, PhD, Licensing and Patenting Manager, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435– 5560; Facsimile: (301) 402–0220; E-mail: mccuepat@mail.nih.gov. SUPPLEMENTARY INFORMATION: This invention concerns methods for the treatment of symptomatic uterine fibroids using a selective progesterone receptor modulator compound, ulipristal acetate (a.k.a. CDB–2914). Ulipristal acetate reversibly binds the progesterone receptor with high affinity and little or no anti-glucocorticoid activity. Proposed clinical indications for ulipristal acetate include emergency/ daily contraception, treatment of uterine fibroids, endometriosis, dysfunctional uterine bleeding, and cancer. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404.7. The prospective exclusive license may be granted unless the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.7 within thirty (30) days from the date of this published notice. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: June 15, 2011. Richard U. Rodriguez, Director, Division of Technology Development & Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2011–15486 Filed 6–21–11; 8:45 am] BILLING CODE 4140–01–P VerDate Mar<15>2010 16:40 Jun 21, 2011 Jkt 223001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License; Devices for Clearing Mucus From Endotracheal Tubes National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of a worldwide exclusive license, to practice the invention embodied in: HHS Ref. No. E–074–2005/0 ‘‘Mucus Slurping Endotracheal Tube’’; U.S. Patent 7,503,328 to Oculus Innovative Sciences, Inc., a company incorporated under the laws of the State of California having its headquarters in Petaluma, California. The United States of America is the assignee of the rights of the above inventions. The contemplated exclusive license may be granted in a field of use limited to devices for clearing mucus from endotracheal tubes. DATES: Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before July 22, 2011 will be considered. SUMMARY: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Michael A. Shmilovich, Esq., Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435– 5019; Facsimile: (301) 402–0220; E-mail: shmilovm@mail.nih.gov. A signed confidentiality nondisclosure agreement will be required to receive copies of any patent applications that have not been published or issued by the United States Patent and Trademark Office or the World Intellectual Property Organization. ADDRESSES: The patent intended for licensure covers a mucus slurping device used to remove mucus before it reaches the tip of the endotracheal tube (ETT). A continuous aspiration endotracheal tube for subglottic secretions is fitted at its distal-most tip with a molded, hollow, concentric plastic ring with 3–4 (or more) small (less than l mm in diameter) suction ports, the latter positioned in the most dependent part of the ETT. A SUPPLEMENTARY INFORMATION: PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 36557 suction line is extended to the tip of the ETT and suction was activated for approximately half of a second, synchronized to the early part of expiration; and repeated once a minute, or as desired. Studies involving intubated sheep showed that all mucus was cleared from test animal and that mucus samples collected showed no infections that typically put patients at risk for ventilator associated pneumonia. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within thirty (30) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: June 14, 2011. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2011–15480 Filed 6–21–11; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Substance Abuse Prevention; Notice of Meeting Pursuant to Public Law 92–463, notice is hereby given of the meeting of the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Prevention (CSAP) Drug Testing Advisory Board (DTAB) on July 12 and 13, 2011. The DTAB will convene in both open and closed sessions over these two days. On July 13 from 10 a.m. to 12:30 p.m. E.D.T., the meeting will be open to the public to review public responses to SAMHSA’s Request for Information on oral fluid as a potential alternative specimen under the Mandatory Guidelines for Federal Workplace Drug Testing Programs. In addition, the E:\FR\FM\22JNN1.SGM 22JNN1 mstockstill on DSK4VPTVN1PROD with NOTICES 36558 Federal Register / Vol. 76, No. 120 / Wednesday, June 22, 2011 / Notices DTAB will deliberate and vote on proposed recommendations. The public is invited to attend the open session in person or to listen via teleconference. Due to the limited seating space and call-in capacity, registration is requested. Public comments are welcome. To register, make arrangements to attend, obtain the teleconference call-in numbers and access codes, submit written or brief oral comments, or to request special accommodations for persons with disabilities, please register at the SAMHSA Advisory Committees’ Web site at https://nac.samhsa.gov/ Registration/meetingsRegistration.aspx or by contacting the CSAP DTAB Designated Federal Official, Dr. Janine Denis Cook (see contact information below). On July 12 between 9 a.m.–4 p.m. E.D.T. and July 13 between 2 p.m. and 4 p.m. E.D.T., the Board will meet in closed session to discuss proposed revisions to the Mandatory Guidelines for Federal Workplace Drug Testing Programs. This portion of the meeting is closed as determined by the Administrator, SAMHSA, in accordance with 5 U.S.C. 552b(c)(9)(B) and 5 U.S.C. App. 2, Section 10(d). Substantive program information, a summary of the meeting, and a roster of DTAB members may be obtained as soon as possible after the meeting, either by accessing the SAMHSA Advisory Committees’ Web site, https:// www.nac.samhsa.gov/DTAB/ meetings.aspx, or by contacting Dr. Cook. The transcript for the open meeting will also be available on the SAMHSA Committee Web site within three weeks after the meeting. Committee Name: Substance Abuse and Mental Health Services, Administration’s Center for Substance Abuse Prevention Drug Testing, Advisory Board. DATES/time/type: July 12, 2011 from 9 a.m. to 4 p.m. E.D.T.: CLOSED. July 13, 2011 from 10 a.m. to 12:30 p.m. E.D.T.: OPEN. July 13, 2011 from 2 p.m. to 4 p.m. E.D.T.: CLOSED. Place: SAMHSA Office Building, Sugarloaf Conference Room, 1 Choke Cherry Road, Rockville, Maryland 20857. Contact: Janine Denis Cook, PhD, Designated Federal Official, SAMHSA Drug Testing Advisory Board, 1 Choke Cherry Road, Room 2–1045, Rockville, Maryland 20857. Telephone: 240–276– 2600, Fax: 240–276–2610, E-mail: janine.cook@samhsa.hhs.gov. VerDate Mar<15>2010 16:40 Jun 21, 2011 Jkt 223001 Dated: June 15, 2011. Carol Rest-Mincberg, Acting Division Director, Division of Workplace Programs, Center for Substance Abuse Prevention, Substance Abuse and Mental Health, Services Administration. Disaster Grants—Public Assistance (Presidentially Declared Disasters); 97.039, Hazard Mitigation Grant. [FR Doc. 2011–15374 Filed 6–21–11; 8:45 am] [FR Doc. 2011–15624 Filed 6–21–11; 8:45 am] BILLING CODE 4162–20–P W. Craig Fugate, Administrator, Federal Emergency Management Agency. BILLING CODE 9111–23–P DEPARTMENT OF HOMELAND SECURITY DEPARTMENT OF HOMELAND SECURITY Federal Emergency Management Agency Federal Emergency Management Agency [Internal Agency Docket No. FEMA–1991– DR; Docket ID FEMA–2011–0001] Illinois; Amendment No. 1 to Notice of a Major Disaster Declaration Federal Emergency Management Agency, DHS. ACTION: Notice. AGENCY: Federal Emergency Management Agency, DHS. This notice amends the notice of a major disaster declaration for the State of Illinois (FEMA–1991–DR), dated June 7, 2011, and related determinations. Effective Date: June 10, 2011. FOR FURTHER INFORMATION CONTACT: Peggy Miller, Office of Response and Recovery, Federal Emergency Management Agency, 500 C Street, SW., Washington, DC 20472, (202) 646–3886. SUPPLEMENTARY INFORMATION: The notice of a major disaster declaration for the State of Illinois is hereby amended to include the Public Assistance program for the following areas among those areas determined to have been adversely affected by the event declared a major disaster by the President in his declaration of June 7, 2011. Alexander, Franklin, Gallatin, Hardin, Jackson, Lawrence, Massac, Perry, Pope, Pulaski, Randolph, Saline, White, and Williamson Counties for Public Assistance (already designated for Individual Assistance). Hamilton, Jefferson, Marion, Union, Wabash, Washington, and Wayne Counties for Public Assistance. The following Catalog of Federal Domestic Assistance Numbers (CFDA) are to be used for reporting and drawing funds: 97.030, Community Disaster Loans; 97.031, Cora Brown Fund; 97.032, Crisis Counseling; 97.033, Disaster Legal Services; 97.034, Disaster Unemployment Assistance (DUA); 97.046, Fire Management Assistance Grant; 97.048, Disaster Housing Assistance to Individuals and Households In Presidentially Declared Disaster Areas; 97.049, Presidentially Declared Disaster Assistance— Disaster Housing Operations for Individuals and Households; 97.050, Presidentially Declared Disaster Assistance to Individuals and Households—Other Needs; 97.036, PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 South Dakota; Amendment No. 2 to Notice of a Major Disaster Declaration AGENCY: SUMMARY: DATES: [Internal Agency Docket No. FEMA–1984– DR; Docket ID FEMA–2011–0001] ACTION: Notice. This notice amends the notice of a major disaster declaration for the State of South Dakota (FEMA–1984– DR), dated May 13, 2011, and related determinations. SUMMARY: DATES: Effective Date: June 8, 2011. FOR FURTHER INFORMATION CONTACT: Peggy Miller, Office of Response and Recovery, Federal Emergency Management Agency, 500 C Street, SW., Washington, DC 20472, (202) 646–3886. The notice of a major disaster declaration for the State of South Dakota is hereby amended to include the following area among those areas determined to have been adversely affected by the event declared a major disaster by the President in his declaration of May 13, 2011. SUPPLEMENTARY INFORMATION: Union County for Public Assistance (already designated for emergency protective measures [Category B], limited to direct Federal assistance, under the Public Assistance program). The following Catalog of Federal Domestic Assistance Numbers (CFDA) are to be used for reporting and drawing funds: 97.030, Community Disaster Loans; 97.031, Cora Brown Fund; 97.032, Crisis Counseling; 97.033, Disaster Legal Services; 97.034, Disaster Unemployment Assistance (DUA); 97.046, Fire Management Assistance Grant; 97.048, Disaster Housing Assistance to Individuals and Households In Presidentially Declared Disaster Areas; 97.049, Presidentially Declared Disaster Assistance— Disaster Housing Operations for Individuals and Households; 97.050, Presidentially Declared Disaster Assistance to Individuals and Households—Other Needs; 97.036, Disaster Grants—Public Assistance E:\FR\FM\22JNN1.SGM 22JNN1

Agencies

[Federal Register Volume 76, Number 120 (Wednesday, June 22, 2011)]
[Notices]
[Pages 36557-36558]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-15374]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Center for Substance Abuse Prevention; Notice of Meeting

    Pursuant to Public Law 92-463, notice is hereby given of the 
meeting of the Substance Abuse and Mental Health Services 
Administration's (SAMHSA) Center for Substance Abuse Prevention (CSAP) 
Drug Testing Advisory Board (DTAB) on July 12 and 13, 2011. The DTAB 
will convene in both open and closed sessions over these two days.
    On July 13 from 10 a.m. to 12:30 p.m. E.D.T., the meeting will be 
open to the public to review public responses to SAMHSA's Request for 
Information on oral fluid as a potential alternative specimen under the 
Mandatory Guidelines for Federal Workplace Drug Testing Programs. In 
addition, the

[[Page 36558]]

DTAB will deliberate and vote on proposed recommendations.
    The public is invited to attend the open session in person or to 
listen via teleconference. Due to the limited seating space and call-in 
capacity, registration is requested. Public comments are welcome. To 
register, make arrangements to attend, obtain the teleconference call-
in numbers and access codes, submit written or brief oral comments, or 
to request special accommodations for persons with disabilities, please 
register at the SAMHSA Advisory Committees' Web site at https://nac.samhsa.gov/Registration/meetingsRegistration.aspx or by contacting 
the CSAP DTAB Designated Federal Official, Dr. Janine Denis Cook (see 
contact information below).
    On July 12 between 9 a.m.-4 p.m. E.D.T. and July 13 between 2 p.m. 
and 4 p.m. E.D.T., the Board will meet in closed session to discuss 
proposed revisions to the Mandatory Guidelines for Federal Workplace 
Drug Testing Programs. This portion of the meeting is closed as 
determined by the Administrator, SAMHSA, in accordance with 5 U.S.C. 
552b(c)(9)(B) and 5 U.S.C. App. 2, Section 10(d).
    Substantive program information, a summary of the meeting, and a 
roster of DTAB members may be obtained as soon as possible after the 
meeting, either by accessing the SAMHSA Advisory Committees' Web site, 
https://www.nac.samhsa.gov/DTAB/meetings.aspx, or by contacting Dr. 
Cook. The transcript for the open meeting will also be available on the 
SAMHSA Committee Web site within three weeks after the meeting.
    Committee Name: Substance Abuse and Mental Health Services, 
Administration's Center for Substance Abuse Prevention Drug Testing, 
Advisory Board.
    DATES/time/type: July 12, 2011 from 9 a.m. to 4 p.m. E.D.T.: 
CLOSED. July 13, 2011 from 10 a.m. to 12:30 p.m. E.D.T.: OPEN. July 13, 
2011 from 2 p.m. to 4 p.m. E.D.T.: CLOSED.
    Place: SAMHSA Office Building, Sugarloaf Conference Room, 1 Choke 
Cherry Road, Rockville, Maryland 20857.
    Contact: Janine Denis Cook, PhD, Designated Federal Official, 
SAMHSA Drug Testing Advisory Board, 1 Choke Cherry Road, Room 2-1045, 
Rockville, Maryland 20857. Telephone: 240-276-2600, Fax: 240-276-2610, 
E-mail: janine.cook@samhsa.hhs.gov.

    Dated: June 15, 2011.
Carol Rest-Mincberg,
Acting Division Director, Division of Workplace Programs, Center for 
Substance Abuse Prevention, Substance Abuse and Mental Health, Services 
Administration.
[FR Doc. 2011-15374 Filed 6-21-11; 8:45 am]
BILLING CODE 4162-20-P